Bio-Techne Corporation (TECH)
- Previous Close
79.55 - Open
79.61 - Bid 80.89 x 200
- Ask 80.98 x 200
- Day's Range
79.47 - 81.08 - 52 Week Range
51.79 - 89.91 - Volume
1,440,078 - Avg. Volume
1,115,328 - Market Cap (intraday)
12.75B - Beta (5Y Monthly) 1.23
- PE Ratio (TTM)
64.73 - EPS (TTM)
1.25 - Earnings Date Aug 6, 2024 - Aug 12, 2024
- Forward Dividend & Yield 0.32 (0.40%)
- Ex-Dividend Date May 10, 2024
- 1y Target Est
83.36
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
www.bio-techne.comRecent News: TECH
Performance Overview: TECH
Trailing total returns as of 5/10/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: TECH
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: TECH
Valuation Measures
Market Cap
12.75B
Enterprise Value
13.10B
Trailing P/E
64.73
Forward P/E
38.31
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
11.30
Price/Book (mrq)
6.33
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
17.59%
Return on Assets (ttm)
6.11%
Return on Equity (ttm)
10.40%
Revenue (ttm)
1.15B
Net Income Avi to Common (ttm)
202.96M
Diluted EPS (ttm)
1.25
Balance Sheet and Cash Flow
Total Cash (mrq)
145.31M
Total Debt/Equity (mrq)
24.56%
Levered Free Cash Flow (ttm)
192.58M
Research Analysis: TECH
Company Insights: TECH
TECH does not have Company Insights